Notice2024-09591

Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
May 3, 2024

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Abstract

The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on May 30, 2024. The topic for this meeting will be "Artificial Intelligence in Diabetes Precision Medicine: Real world data, real world opportunities and challenges". The meeting is open to the public.

Full Text

<html>
<head>
<title>Federal Register, Volume 89 Issue 87 (Friday, May 3, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 87 (Friday, May 3, 2024)]
[Notices]
[Pages 36825-36826]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-09591]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Diabetes Mellitus Interagency Coordinating Committee 
Meeting

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee 
(DMICC) will hold a meeting on May 30, 2024. The topic for this meeting 
will be ``Artificial Intelligence in Diabetes Precision Medicine: Real 
world data, real world opportunities and challenges''. The meeting is 
open to the public.

DATES: The meeting will be held on May 30, 2024 from 12:00 p.m. to 3:30 
p.m. EDT.

ADDRESSES: The meeting will be held via the Zoom online video 
conferencing platform. For details, and to register, please contact 
<a href="/cdn-cgi/l/email-protection#781c15111b1b381519111456161110561f170e"><span class="__cf_email__" data-cfemail="5430393d37371439353d387a3a3d3c7a333b22">[email&#160;protected]</span></a>.

FOR FURTHER INFORMATION CONTACT: For further information concerning 
this meeting, including a draft agenda, which will be posted when 
available, see the DMICC website, <a href="https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022">https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022</a>, or contact Dr. William 
Cefalu, Executive Secretary of the Diabetes Mellitus Interagency 
Coordinating Committee, National Institute of Diabetes and Digestive 
and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, 
Bethesda, MD 20892, telephone: 301-435-1011; email: <a href="/cdn-cgi/l/email-protection#07636a6e6464476a666e6b29696e6f29606871"><span class="__cf_email__" data-cfemail="2c4841454f4f6c414d454002424544024b435a">[email&#160;protected]</span></a>.

SUPPLEMENTARY INFORMATION: In accordance with 42 U.S. Code 285c-3, the 
DMICC, chaired by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) comprising members of the Department of Health 
and Human Services and other federal agencies that support diabetes-
related activities, facilitates cooperation, communication, and 
collaboration on diabetes among government entities. DMICC meetings, 
held several times a year, provide an opportunity for Committee members 
to learn about and discuss current and future diabetes programs in 
DMICC member organizations and to identify opportunities for 
collaboration. The May 30, 2024 DMICC meeting will focus on 
``Artificial Intelligence in Diabetes Precision Medicine: Real world 
data, real world opportunities and challenges.''
    Any member of the public interested in presenting oral comments to 
the Committee should notify the contact person listed on this notice at 
least 5 days in advance of the meeting. Interested individuals and 
representatives or organizations should submit a letter of intent, a 
brief description of the organization represented, and a written copy 
of their oral presentation in advance of the

[[Page 36826]]

meeting. Only one representative of an organization will be allowed to 
present; oral comments and presentations will be limited to a maximum 
of 5 minutes. Printed and electronic copies are requested for the 
record. In addition, any interested person may file written comments 
with the Committee by forwarding their statement to the contact person 
listed on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person. Because of time constraints for 
the meeting, oral comments will be allowed on a first-come, first-serve 
basis.
    Members of the public who would like to receive email notification 
about future DMICC meetings should register for the listserv available 
on the DMICC website, <a href="https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022">https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022</a>.

William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, 
National Institute of Diabetes and Digestive and Kidney Diseases, and 
Metabolic Diseases, National Institutes of Health.
[FR Doc. 2024-09591 Filed 5-2-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on May 3, 2024.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.